News
Company News
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally adv
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-targ
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceuti
-
2025.10 20
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally adv
-
2025.09 17
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-targ
-
2025.08 18
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceuti
-
2025.08 13
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase I
-
2025.08 08
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
YANTAI, China, Aug. 8, 2025 /PRNewswire/ -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed
-
2025.06 03
2025 ASCO ｜ Selected in Rapid Oral Abstract Presentation: Disitamab Vedotin as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer Achieves Efficacy Breakthrough
Chicago, US, June 2, 2025 (UTC-8)—In a rapid oral abstract session of the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the result of a Phase 2 clinical trial conducted in China to evaluate the efficacy and safety of
-
2025.06 02
2025 ASCO | RemeGen Announces Trial Results of c-Met Targeted ADC for Treatment of Non-small Cell Lung Cancer
At the 2025 ASCO Annual Meeting, RemeGen presented data from phase 1b/2 clinical trial of RC108 in combination with furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on EGFR-TKI treatment,
-
2025.05 27
RemeGen’s Telitacicept Approved for Treatment of Myasthenia Gravis in China
On May 27th, RemeGen Co., Ltd. (688331.SH / 09995.HK) announced that its independently-designed and -developed novel fusion protein targeting both BLyS and APRIL, telitacicept (synonym: RC18, brand name: 泰爱®), was approved for marketing by China’s
-
2025.05 12
RemeGen’s Novel ADC Drug RC278’s Clinical Trial Application Accepted
On May 12th, RemeGen Co., Ltd. (688331.SH/9995.HK) announced that the Clinical Trial Application (CTA) for its novel ADC Drug RC278 has been submitted recently and accepted by National Medical Products Administration (NMPA) Center for Drug Reevaluation (C
-
2025.05 12
Poised to Reshape Treatment Landscape: A Phase 3 Clinical Trial on Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
On May 12, 2025, RemeGen Co., Ltd. (“RemeGen”, stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (NCT05302284, study ID: RC48-C016) on disitamab vedotin (DV, brand name: Aidixi®), an anti-HER2 antibody-drug conjugate (ADC),
Press Release
-
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
First patient enrolled in Telitacicept IgA nephropathy PhaseⅡclinical trial in the U.S.
more
No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.
（+86）535-3573511
Official WeChat